Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40264-016-0405-1 http://scihub22266oqcxt.onion/10.1007/s40264-016-0405-1 C4871909!4871909 !26951233     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26951233 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Drug+Saf 2016 ; 39 (6 ): 469-90 Nephropedia Template TP {{tp|p=26951233 |t=2016. Good Signal Detection Practices: Evidence from IMI PROTECT |pdf=|usr=}}{{26951233 }} gab.com Text Good Signal Detection Practices: Evidence from IMI PROTECT JO: Drug Saf http://www.kidney.de/pget.php?&tw=1&pmid=26951233 #FOAvip Over a period of 5 years, the Innovative Medicines Initiative PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) project has addressed key research questions relevant to the science of safety signal detection. The results of studies conducted into quantitative signal detection in spontaneous reporting, clinical trial and electronic health records databases are summarised and 39 recommendations have been formulated, many based on comparative analyses across a range of databases (e.g. regulatory, pharmaceutical company). The recommendations point to pragmatic steps that those working in the pharmacovigilance community can take to improve signal detection practices, whether in a national or international agency or in a pharmaceutical company setting. PROTECT has also pointed to areas of potentially fruitful future research and some areas where further effort is likely to yield less. Twit Text FOAVip Good Signal Detection Practices: Evidence from IMI PROTECT ????Drug Saf http://www.kidney.de/pget.php?&tw=1&pmid=26951233 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26951233 #FOAvip English Wikipedia <ref>{{Cite pmid|26951233 }}</ref> Good Signal Detection Practices: Evidence from IMI PROTECT #MMPMID26951233 Wisniewski AF ; Bate A ; Bousquet C ; Brueckner A ; Candore G ; Juhlin K ; Macia-Martinez MA ; Manlik K ; Quarcoo N ; Seabroke S ; Slattery J ; Southworth H ; Thakrar B ; Tregunno P ; Van Holle L ; Kayser M ; Norén GN Drug Saf 2016[Jun]; 39 (6 ): 469-90 PMID26951233 show ga Over a period of 5 years, the Innovative Medicines Initiative PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) project has addressed key research questions relevant to the science of safety signal detection. The results of studies conducted into quantitative signal detection in spontaneous reporting, clinical trial and electronic health records databases are summarised and 39 recommendations have been formulated, many based on comparative analyses across a range of databases (e.g. regulatory, pharmaceutical company). The recommendations point to pragmatic steps that those working in the pharmacovigilance community can take to improve signal detection practices, whether in a national or international agency or in a pharmaceutical company setting. PROTECT has also pointed to areas of potentially fruitful future research and some areas where further effort is likely to yield less. |Adverse Drug Reaction Reporting Systems/*standards [MESH] |Databases, Factual/*standards [MESH] |Drug-Related Side Effects and Adverse Reactions/*epidemiology [MESH] |Europe [MESH] |Humans [MESH] |Pharmacovigilance [MESH]Good Signal Detection Practices: Evidence from IMI PROTECT (epmc).pdf DeepDyve Pubget Overpricing